THE SIGNS OF CARBOHYDRATE-LIPID METABOLISM DISTURBANCE IN PATIENTS WITH CHRONIC HEPATITIS C
Abstract
Background. Viral hepatitis C (CHC) is an urgent problem due to its prevalence, high risk of developing liver cirrhosis and hepatocellular carcinoma. Viral hepatitis C can cause disruption of many biochemical processes in the liver cells, primarily that of carbohydrate - lipid metabolism. Objective. To study carbohydrate-lipid metabolism disturbances in patients with CHC. Material and methods. The study included 124 patients with paucisymptomatic chronic hepatitis C. The metabolic syndrome was diagnosed according to the indicators recommended by the Committee of Experts of the Russian Society of Cardiology (2007). Results. The parameters of lipid metabolism were studied in 52 of 124 patients with CHC. 29 of 52 patients with CHC (55.7%) showed a decrease in HDL cholesterol and an increase in LDL cholesterol, including a 2- fold increase in VLDL. The metabolic syndrome was detected in 22.5% of patients with CHC, 62.9% of patients had the manifestations of dyslipidemia (steatosis or steatohepatitis of the liver, obesity, arterial hypertension, insulin resistance, type 2 diabetes mellitus). Conclusions. In patients with CHC, carbohydrate-lipid metabolism disturbance was revealed as an integral indicator of metabolic syndrome, its incidence rising with the increase in activity and duration of the infectious process.References
Ivashkin VT, Mayevskaya MV, Abdurakhmanov DT, Bakulin IG, Geyvandova NI, Zubkin ML, Kizhlo SN, Kuznetsova AV, Latysheva IB, Mamonova NA, Morozov VG, Sagalova OI, Esaulenko YeV, Lyusina YeO. Sovremennye vozmozhnosti protivovirusnoj terapii s ispolzovaniem daklatasvira pri lechenii bolnyh hronicheskim virusnym gepatitom C: rezultaty programmy individualnogo dostupa [The modern options of chronic hepatitis c antiviral therapy with daclatasvir: results of named patient program]. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii [The Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2017;27(6):52-62. (Russian).
Uyshuk ND, Ivakhnenko OI, Znoyko OO, Klimova EA, Dudina KR, Beliy PA, Zayratyants OV, Omelyanovskiy VV. Modeling the epidemiological situation with viral hepatitis C in the Russian Federation: opportunities and challenges. Infekcionnye bolezni [Infectious Diseases]. 2019;17(1):105- 114. https://doi.org/10.20953/1729-9225-2019-1-105-114.
Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-562. https://doi.org/10.1038/nrgastro.2013.107.
Chen CJ. Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. Gut. 2018;67(4):595-598. https://doi.org/10.1136/gutjnl-2017-315407.
Mutimer DJ, Lok A. Management of HBV- and HCV-induced end stage liver disease. Gut. 2012;61(Suppl 1):i59-i67. https://doi.org/10.1136/gutjnl-2012-302076.
World Health Organization. Global Hepatitis Report, 2017. Geneva: World Health Organization; 2017. 83 p. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-2128. https://doi.org/10.1016/S0140-6736(12)61728-0.
Zhdanov KV, Ivanov AM, Jaremenko MV, Zaharenko SM, Kozlov KV, Bulankov JuI, Shahmanov DM, Zhabrov SS, Sukachev VS, Zharnastanova GA, Saulevich AV, Karjakin SS. Metabolicheskij sindrom pri NCV-infekcii. In: V Kongress Evro-Aziatskogo obshhestva po infekcionnym boleznjam; 2018 May 16-18; Novosibirsk. Zhurnal infektologii [Journal Infectology]. 2018;10(2):45-46. (Russian).
Tkachenko LI, Maleev VV, Cvetkovskaja TN. Rol ozhirenija v razvitii metabolicheskih narushenij, progressirovanii fibroza pecheni i ishodov protivovirusnoj terapii u bolnyh hronicheskim gepatitom C [Role of obesity in the development of metabolic disorders, in the progression of liver fibrosis, and in the outcomes of antiviral therapy in patients with chronic hepatitis C] Jepidemiologija i infekcionnye bolezni. Aktualnye voprosy [Epidemiology and infectious diseases. Current items]. 2016;1:22-31. (Russian).
Kukla M, Mazur W, Bułdak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspin-in chronic hepatitis. Mol Med. 2011;17(11-12):1397-410. https://doi.org/10.2119/molmed.2010.00105.
Kawaguchi Y, Mizuta T. Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol. 2014;20(11):2888-2901. https://doi.org/10.3748/wjg.v20.i11.2888.
Polupanov AG, Kontsevaya AV, Mamasaidov ZhA, Khalmatov AN, Altymysheva AT, Dzhumagulova AS. Rasprostranjonnost metabolicheskogo sindroma i ego komponentov sredi zhitelej Kyrgyzskoj Respubliki trudosposobnogo vozrasta [Prevalence of metabolic syndrome and its components among working-age residents of the Kyrgyz Republic]. Kazanskij medicinskij zhurnal [Kazan medical journal]. 2016;97(4):618-624. https://doi.org/10.17750/KMJ2015-618. https://doi.org/10.17750/KMJ2015-618. (Russian).
Ahmed GM, Adam AA. Seroprevalence of hepatitis C virus among type 2 diabetes mellitus patients in blue nile state, Sudan. American Journal of Research Communication. 2014;2(12):141-147.
Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014;5(1):52-58. https://doi.org/10.4239/wjd.v5.i1.52.
1.png)
